The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | Tools for monitoring bone disease in multiple myeloma
In this video, Marco Talarico, MD, University of Bologna, Bologna, Italy, briefly discusses the monitoring of bone disease in patients with multiple myeloma (MM). Dr Talarico highlights that CT scans are recommended for assessing the size of plasmacytomas and monitoring their size during treatment, while PET-CT is recommended for evaluating metabolic activity of lesions and assessing imaging measurable residual disease (MRD). Dr Talarico also mentions that whole-body diffusion-weighted MRI has shown good concordance with PET-CT in response assessment, suggesting its potential as an alternative tool. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
CT is currently recommended for the assessment of size of plasmacytomas and for the monitoring of their size during treatment, whereas PET-CT is recommended for the assessment of metabolic activity of lesions and in follow-up regarding the assessment of imaging MRD. However, the assessment of response by whole body diffusion-weighted MRI using Myeloma Response Assessment and Diagnosis (MY-RADS) criteria, and in particular the so-called response assessment categories, has proven significantly prognostic...
CT is currently recommended for the assessment of size of plasmacytomas and for the monitoring of their size during treatment, whereas PET-CT is recommended for the assessment of metabolic activity of lesions and in follow-up regarding the assessment of imaging MRD. However, the assessment of response by whole body diffusion-weighted MRI using Myeloma Response Assessment and Diagnosis (MY-RADS) criteria, and in particular the so-called response assessment categories, has proven significantly prognostic. Similarly to assessment of metabolic response by PET using IMPeTUs criteria. And in our study, early evaluation of concordance between PET-CT and whole-body diffusion-weighted MRI regarding response assessment has displayed a very good concordance between the two techniques, thus suggesting that whole-body diffusion-weighted MRI can be alternatively used to PET-CT regarding response assessment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
